Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in @entity164 2 @entity6 XXXX .

@entity1 @entity6 @entity8993 @entity28371 @entity6511 @entity1675 @entity164 @entity3294
UNASSIGNED: HDL-increasing drugs such as fenofibrate and niacin have failed to decrease the cardiovascular risk in @entity1 with @entity164 2 @entity6 . Drug-mediated quantitative and qualitative HDL modifications could be involved in these negative results. To evaluate the quantitative and qualitative effects of niacin and fenofibrate on HDL in @entity1 with @entity164 2 @entity6 , a prospective, randomised controlled intervention trial was conducted. Thirty @entity164 2 @entity6 @entity1 with low HDL were randomised to receive either fenofibrate (FFB) or niacin  +  laropiprant (ERN/LPR) as an add-on to simvastatin treatment for 12 weeks according to a crossover design. At the basal point and after each intervention period, physical examinations and comprehensive standard biochemical determinations and HDL metabolomics were performed. Thirty nondiabetic @entity1 with normal HDL were used as a basal control group. ERN/ @entity8993 , but not FFB, significantly increased HDL cholesterol. Neither ERN/ @entity8993 nor FFB reversed the HDL particle size or particle number to normal. ERN/ @entity8993 increased @entity1675 but not @entity3294 , whereas FFB produced the opposite effect. FFB significantly increased Preb1-HDL, whereas ERN/ @entity8993 tended to lower Preb1-HDL. @entity28371 and LCAT activities were significantly decreased only by ERN/ @entity8993 . @entity6511 activity in HDL and plasma decreased with the use of both agents. Despite their different actions on antioxidant parameters, none of the treatments induced detectable antioxidant improvements. ERN/ @entity8993 had strikingly different effects on HDL quantity and quality, as well as on HDL cholesterol concentrations. When prescribing HDL cholesterol increasing drugs, this differential action should be considered.
